Savara Grants Equity Awards to 24 New Hires

Biopharmaceutical company issues stock options, RSUs, and PSUs as inducement for new employees.

Apr. 17, 2026 at 8:05pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a stack of pharmaceutical vials and syringes arranged elegantly on a clean, monochromatic background, conveying a sense of precision, innovation, and corporate strategy in the biopharmaceutical industry.Savara's strategic investment in new talent through equity awards signals the company's commitment to advancing its pipeline of rare respiratory disease treatments.Langhorne Today

Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, has announced the grant of inducement awards to 24 new employees who recently joined the company. The awards include options to purchase 18,500 shares, 141,000 restricted stock units (RSUs), and 85,000 performance stock units (PSUs).

Why it matters

The equity awards are part of Savara's strategy to attract and retain top talent in the highly competitive biopharmaceutical industry. Offering competitive compensation packages, including stock-based incentives, is crucial for smaller biotech firms to build out their teams and advance their drug development pipelines.

The details

The options have an exercise price of $6.07 per share, which was the closing trading price of Savara's common stock on the grant date. The options vest quarterly over two years, while the RSUs and PSUs vest based on continued employment and the achievement of a revenue target, respectively.

  • On April 14, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards.
  • The options have a 10-year term.

The players

Savara Inc.

A clinical-stage biopharmaceutical company focused on rare respiratory diseases.

MOLBREEVI

Savara's lead program, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

Got photos? Submit your photos here. ›

The takeaway

Savara's equity awards to new hires demonstrate the company's commitment to building a strong team to advance its pipeline of rare respiratory disease treatments. Competitive compensation packages, including stock-based incentives, are crucial for smaller biotech firms to attract and retain top talent in a highly competitive industry.